tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CNTX Stock Latest News

Buy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
RatingsBuy Rating for Context Therapeutics: Strong Financials and Promising Clinical Developments
4d ago
CNTX
Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting
PremiumThe Fly
Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting
4d ago
CNTX
Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright
PremiumThe Fly
Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright
5d ago
CNTX
Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating
PremiumRatings
Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating
5d ago
CNTX
Context Therapeutics Reports Improved Quarterly Results
PremiumCompany Announcements
Context Therapeutics Reports Improved Quarterly Results
5d ago
CNTX
Context Therapeutics reports Q3 EPS (10c), consensus (9c)
PremiumThe FlyContext Therapeutics reports Q3 EPS (10c), consensus (9c)
5d ago
CNTX
Context Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Context Therapeutics Reports Q3 2025 Financial Results
5d ago
8K
CNTX
Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
Premium
Company Announcements
Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study
14d ago
CNTX
Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment
PremiumCompany Announcements
Context Therapeutics’ CT-95 Study: A Potential Game-Changer in Cancer Treatment
14d ago
CNTX
Context Therapeutics Amends Sales Agreement with Leerink
PremiumCompany Announcements
Context Therapeutics Amends Sales Agreement with Leerink
17d ago
8K
CNTX
Context Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Context Therapeutics Regains Nasdaq Compliance
21d ago
8K
CNTX
Context Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Context Therapeutics initiated with an Overweight at Cantor Fitzgerald
1M ago
CNTX
Context Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyContext Therapeutics initiated with an Overweight at Cantor Fitzgerald
1M ago
CNTX
Context Therapeutics management to meet with Maxim
Premium
The Fly
Context Therapeutics management to meet with Maxim
1M ago
CNTX
Context Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Context Therapeutics initiated with a Buy at Guggenheim
2M ago
CNTX
Context Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Context Therapeutics initiated with a Buy at Guggenheim
2M ago
CNTX
Context Therapeutics management to meet with Maxim
PremiumThe Fly
Context Therapeutics management to meet with Maxim
2M ago
CNTX
Context Therapeutics Granted Nasdaq Extension for Compliance
PremiumCompany Announcements
Context Therapeutics Granted Nasdaq Extension for Compliance
2M ago
8K
CNTX
Context Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Context Therapeutics Reports Q2 2025 Financial Results
3M ago
CNTX
Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
PremiumThe FlyContext Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
3M ago
CNTX
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
Premium
The Fly
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
3M ago
CNTX
Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler
Premium
The Fly
Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler
5M ago
CNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >